Enliven Therapeutics (ELVN) Insider Trading & Ownership $22.01 -0.59 (-2.61%) (As of 07/19/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Enliven Therapeutics (NASDAQ:ELVN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)10Amount OfInsider Selling(Last 12 Months)$50.08 M Get ELVN Insider Trade Alerts Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ELVN Insider Buying and Selling by Quarter Ad DTIIs Apple out of “juice” at a $3.5T market cap? In roughly 40 years, Apple went from a little-known garage startup… To a multi-trillion dollar global corporation trading at all-time highs of over $200 per share. Many “experts” believe the stock’s wildly overvalued… But Apple’s investment in artificial intelligence could trigger an AI-fueled frenzy. And there’s a little-know strategy traders can use to tap into the AI craze.All you need to do is click right here for a special message. Enliven Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/15/2024Anish PatelCOOSell30,978$25.05$775,998.90 7/15/2024Richard A HeymanDirectorSell1,270$24.80$31,496.00 7/12/2024Anish PatelCOOSell17,475$25.07$438,098.25 7/12/2024Benjamin HohlCFOSell3,000$25.07$75,210.00 6/27/2024Benjamin HohlCFOSell4,250$22.57$95,922.50 6/25/2024Samuel KintzCEOSell12,000$21.66$259,920.00 Is Apple out of “juice” at a $3.5T market cap? (Ad)In roughly 40 years, Apple went from a little-known garage startup… To a multi-trillion dollar global corporation trading at all-time highs of over $200 per share. Many “experts” believe the stock’s wildly overvalued… But Apple’s investment in artificial intelligence could trigger an AI-fueled frenzy. And there’s a little-know strategy traders can use to tap into the AI craze.All you need to do is click right here for a special message.6/6/2024Anish PatelCOOSell1,133$20.06$22,727.98 5/28/2024Benjamin HohlCFOSell4,250$23.18$98,515.00 5/28/2024Samuel KintzCEOSell12,000$23.18$278,160.00 5/16/2024Rishi GuptaDirectorSell1,033,300$22.14$22,877,262.00 5/14/2024Anish PatelCOOSell1,107$25.00$27,675.00 5/9/2024Anish PatelCOOSell260$25.06$6,515.60 5/6/2024Anish PatelCOOSell4,875$22.72$110,760.00 5/3/2024Benjamin HohlCFOSell1,000$22.50$22,500.00 4/29/2024Benjamin HohlCFOSell3,250$16.97$55,152.50 4/29/2024Joseph P. LyssikatosinsiderSell12,000$17.92$215,040.00 4/25/2024Samuel KintzCEOSell12,000$16.89$202,680.00 4/15/2024Richard A HeymanDirectorSell1,270$19.99$25,387.30 4/11/2024Anish PatelCOOSell17,500$25.03$438,025.00 4/11/2024Benjamin HohlCFOSell14,000$24.72$346,080.00 4/11/2024Joseph P. LyssikatosinsiderSell30,000$25.04$751,200.00 4/11/2024Rahul D BallalDirectorSell53,400$23.95$1,278,930.00 4/11/2024Samuel KintzCEOSell47,709$25.04$1,194,633.36 4/8/2024Anish PatelCOOSell4,875$18.60$90,675.00 4/4/2024Rahul D BallalDirectorSell3,485$19.15$66,737.75 4/1/2024Joseph P. LyssikatosinsiderSell12,000$18.60$223,200.00 4/1/2024Rahul D BallalDirectorSell3,237$19.08$61,761.96 3/27/2024Benjamin HohlCFOSell3,250$18.25$59,312.50 3/25/2024Samuel KintzCEOSell12,000$17.56$210,720.00 3/19/2024Richard A HeymanDirectorSell1,270$14.50$18,415.00 3/6/2024Anish PatelCOOSell4,875$15.64$76,245.00 2/29/2024Joseph P. LyssikatosinsiderSell12,000$16.42$197,040.00 2/27/2024Benjamin HohlCFOSell3,250$16.97$55,152.50 2/15/2024Richard A HeymanDirectorSell1,270$17.42$22,123.40 2/6/2024Anish PatelCOOSell4,875$15.11$73,661.25 1/31/20245Am Partners Vi, LlcMajor ShareholderSell500,000$15.00$7,500,000.00 1/30/2024Richard A HeymanDirectorSell1,270$16.41$20,840.70 1/29/2024Benjamin HohlCFOSell3,250$15.81$51,382.50 1/29/2024Joseph P. LyssikatosinsiderSell12,000$15.85$190,200.00 1/25/2024Samuel KintzCEOSell12,000$15.69$188,280.00 New Government Policy to Wipe Out Seniors Wealth (Ad)Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now!1/22/2024Anish PatelCOOSell4,875$15.13$73,758.75 1/2/2024Anish PatelCOOSell11,000$15.00$165,000.00 1/2/2024Benjamin HohlCFOSell9,383$15.01$140,838.83 12/26/2023Anish PatelCOOSell102$15.01$1,531.02 12/26/2023Benjamin HohlCFOSell100$15.00$1,500.00 12/26/2023Samuel KintzCEOSell12,000$14.64$175,680.00 12/22/2023Anish PatelCOOSell983$15.03$14,774.49 12/22/2023Benjamin HohlCFOSell1,030$15.07$15,522.10 12/22/2023Samuel KintzCEOSell8,175$13.05$106,683.75 12/21/2023Joseph P. LyssikatosinsiderSell20$13.00$260.00 12/21/2023Richard A HeymanDirectorSell7$13.00$91.00 12/20/2023Samuel KintzCEOSell7,779$13.01$101,204.79 12/19/2023Joseph P. LyssikatosinsiderSell200$13.00$2,600.00 12/19/2023Richard A HeymanDirectorSell255$13.00$3,315.00 11/3/2023Joseph P. LyssikatosinsiderSell8,546$13.08$111,781.68 11/3/2023Samuel KintzCEOSell8,026$13.08$104,980.08 9/29/2023Joseph P. LyssikatosinsiderSell12,000$13.62$163,440.00 9/26/20235Am Partners Vi, LlcMajor ShareholderSell197,500$15.00$2,962,500.00 9/25/2023Samuel KintzCEOSell12,000$13.81$165,720.00 8/24/20235Am Partners Vi, LlcMajor ShareholderSell440,000$16.00$7,040,000.00 (Data available from 1/1/2013 forward) ELVN Insider Trading Activity - Frequently Asked Questions Who is on Enliven Therapeutics's Insider Roster? The list of insiders at Enliven Therapeutics includes 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P. Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta, and Samuel Kintz. Learn more on insiders at ELVN. What percentage of Enliven Therapeutics stock is owned by insiders? 29.20% of Enliven Therapeutics stock is owned by insiders. Learn more on ELVN's insider holdings. Which Enliven Therapeutics insiders have been selling company stock? The following insiders have sold ELVN shares in the last 24 months: 5Am Partners Vi, Llc ($17,502,500.00), Anish Patel ($2,315,446.24), Benjamin Hohl ($1,017,088.43), Joseph P. Lyssikatos ($1,854,761.68), Rahul D Ballal ($1,407,429.71), Richard A Heyman ($121,668.40), Rishi Gupta ($22,877,262.00), and Samuel Kintz ($2,988,661.98). How much insider selling is happening at Enliven Therapeutics? Insiders have sold a total of 2,646,915 Enliven Therapeutics shares in the last 24 months for a total of $50,084,818.44 sold. More Insider Trading Tools from MarketBeat Related Companies: Avadel Pharmaceuticals Insider Buying Fulcrum Therapeutics Insider Buying Editas Medicine Insider Buying Delcath Systems Insider Buying bluebird bio Insider Buying Orgenesis Insider Buying Lyra Therapeutics Insider Buying Intellia Therapeutics Insider Buying Avidity Biosciences Insider Buying Crinetics Pharmaceuticals Insider Buying Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: What Does Market Rotation Mean for This Top AI Stock?3 Beaten Down Stocks That Insiders Are Buying3 Insider-Buy Stocks to Add to Your Watchlist NowNVIDIA Stock Defies Skeptics, Earns Analyst Upgrade3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace This page (NASDAQ:ELVN) was last updated on 7/20/2024 by MarketBeat.com Staff From Our PartnersRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGet in before Reddit doesRobinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Enliven Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
